Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shaftesbury Capital upbeat on thriving West End

(Sharecast News) - Shaftesbury Capital posted a jump in its portfolio valuation on Thursday, despite the weaker macroeconomic backdrop, as its properties in London's West End continued to perform well. The valuation of Shaftesbury's portfolio - which spans Covent Garden, Soho, Carnaby Street and Chinatown - increased by 4.5% on a like-by-like basis in 2024, to £5bn. Estimated rental value (ERV) growth of 7.7% helped offset an outward yield movement of 13 basis points.

Underlying earnings increased by 16.2% to 4p per share, while annualised gross income rose 8% to £202.8m.

Ian Hawksworth, chief executive, said: "Our West End estates continue to be busy and vibrant with high footfall and customer sales growth.

"There continues to be strong leasing demand with 473 transactions completed 9% ahead of December 2023 ERV, with an excellent leasing pipeline."

Looking ahead, the real estate investment trust said the West End was continuing to "perform" despite the "well-documented macroeconomic uncertainty".

It continued: "Footfall is high, with continued customer sales growth, limited vacancy and strong leasing pipeline.

"The quality of our portfolio, our active approach and the positive market fundamentals of the West End give us confidence in our target to 5% to 7% rental growth, which will table yields, would deliver total accounting returns of 8% to 10% over the medium term."

As at 1000 GMT, shares in the FTSE 250 company were down 2% at 122.7p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.